This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gratas, C. Articles by Ohgaki, H. Search for Related Content PubMed PubMed Citation Articles by Gratas, C. Articles by Ohgaki, H.

Up-Regulation of Fas (APO-1/CD95) Ligand and Down-Regulation of Fas Expression in Human Esophageal Cancer¹

Units of Molecular Pathology [C. G., Y. T., H. O.] and Mechanisms of Carcinogenesis [C. B., P. T., P. H.], International Agency for Research on Cancer, 69372 Lyon Cedex 08, France

Fas (APO-1/CD95) is a cell surface receptor that mediates apoptosis when it reacts with Fas ligand (FasL) or Fas antibody. In this study, we analyzed Fas and FasL expression in normal esophageal mucosa and esophageal squamous cell carcinomas. Reverse transcriptase-PCR revealed that Fas, soluble Fas, and FasL were expressed in all eight esophageal squamous carcinoma cell lines analyzed. Furthermore, it was demonstrated that FasL expressed in esophageal carcinoma cells is functional because coculture experiments using FasL-expressing TE-15 esophageal carcinoma cells resulted in apoptosis of Jurkat T leukemia cells, which are sensitive to Fas-mediated apoptosis. Immunohistochemistry of Fas and FasL showed that they are constitutively expressed in normal esophageal mucosa, FasL being predominantly in the basal and suprabasal layers, whereas Fas is in more differentiated layers, i.e., rows of polyhedral cells of the intermediate layers and squamous cells forming the outer layers. In 18 of 19 invasive esophageal squamous cell carcinomas, FasL expression was found in >50% of tumor cells. In contrast, most tumors (15 of 19, 79%) either showed no Fas expression or showed expression in <5% of tumor cells. These alterations were already detected in dysplasia and carcinoma in situ. These results suggest that up-regulation of FasL and down-regulation of Fas expression are early and frequent events associated with the evolution of esophageal squamous cell carcinomas.

¹ C. B. was supported by the Fonds zur Förderung der Wissenschaftlichen Forschung, Erwin Schrödinger Auslandsstipendium Nr. J01271-MED, Austria.

² To whom requests for reprints should be addressed, at Unit of Molecular Pathology, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France. Phone: 33-472-73-85-34; Fax: 33-472-73-85-64; E-mail: ohgaki@iarc.fr.

Received 1/20/97. Accepted 3/31/98.

This article has been cited by other articles:

				Y. Guo, Z. Chen, L. Zhang, F. Zhou, S. Shi, X. Feng, B. Li, X. Meng, X. Ma, M. Luo, et al. Distinctive MicroRNA Profiles Relating to Patient Survival in Esophageal Squamous Cell Carcinoma Cancer Res., January 1, 2008; 68(1): 26 - 33. [Abstract] [Full Text] [PDF]

				K W Chan, P Y Lee, A K Y Lam, S Law, J Wong, and G Srivastava Clinical relevance of Fas expression in oesophageal squamous cell carcinoma J. Clin. Pathol., January 1, 2006; 59(1): 101 - 104. [Abstract] [Full Text] [PDF]

				B. Huang, J. Zhao, H. Li, K.-L. He, Y. Chen, L. Mayer, J. C. Unkeless, and H. Xiong Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance Cancer Res., June 15, 2005; 65(12): 5009 - 5014. [Abstract] [Full Text] [PDF]

				X Zhang, X Miao, T Sun, W Tan, S Qu, P Xiong, Y Zhou, and D Lin Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer J. Med. Genet., June 1, 2005; 42(6): 479 - 484. [Abstract] [Full Text] [PDF]

				T. Sun, X. Miao, X. Zhang, W. Tan, P. Xiong, and D. Lin Polymorphisms of Death Pathway Genes FAS and FASL in Esophageal Squamous-Cell Carcinoma J Natl Cancer Inst, July 7, 2004; 96(13): 1030 - 1036. [Abstract] [Full Text] [PDF]

				C. D. Riffkin, A. Z. Gray, C. J. Hawkins, C.W. Chow, and D. M. Ashley Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction Neuro-oncol, October 1, 2001; 3(4): 229 - 240. [Abstract] [PDF]

				S. Weisberg, E. Ashkenazi, Z. Israel, M. Attia, Y. Shoshan, F. Umansky, and C. Brodie Anaplastic and Atypical Meningiomas Express High Levels of Fas and Undergo Apoptosis in Response to Fas Ligation Am. J. Pathol., October 1, 2001; 159(4): 1193 - 1197. [Abstract] [Full Text]

				F. M. Yakes, B. D. Wamil, F. Sun, H.-P. Yan, C. E. Carter, and C. G. Hellerqvist CM101 Treatment Overrides Tumor-induced Immunoprivilege Leading to Apoptosis Cancer Res., October 1, 2000; 60(20): 5740 - 5746. [Abstract] [Full Text]

				C. M. Mueller and D. W. Scott Distinct Molecular Mechanisms of Fas Resistance in Murine B Lymphoma Cells J. Immunol., August 15, 2000; 165(4): 1854 - 1862. [Abstract] [Full Text] [PDF]

				L. HEFLER, K. MAYERHOFER, A. NARDI, A. REINTHALLER, C. KAINZ, and C. TEMPFER Serum Soluble Fas Levels in Ovarian Cancer Obstet. Gynecol., July 1, 2000; 96(1): 65 - 69. [Abstract] [Full Text] [PDF]

				G. Bellone, C. Smirne, A. Carbone, K. Mareschi, L. Dughera, E. C. Farina, O. Alabiso, G. Valente, G. Emanuelli, and U. Rodeck Production and Pro-Apoptotic Activity of Soluble CD95 Ligand in Pancreatic Carcinoma Clin. Cancer Res., June 1, 2000; 6(6): 2448 - 2455. [Abstract] [Full Text]

				B. R. Gastman, D. E. Johnson, T. L. Whiteside, and H. Rabinowich Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events Blood, March 15, 2000; 95(6): 2015 - 2023. [Abstract] [Full Text] [PDF]

				C. G. Ferreira, C. Tolis, S. W. Span, G. J. Peters, T. van Lopik, A. J. Kummer, H. M. Pinedo, and G. Giaccone Drug-induced Apoptosis in Lung Cancer Cells Is Not Mediated by the Fas/FasL (CD95/APO1) Signaling Pathway Clin. Cancer Res., January 1, 2000; 6(1): 203 - 212. [Abstract] [Full Text]

				P. L. Arscott, T. Stokes, A. Myc, T. J. Giordano, N. W. Thompson, and J. R. Baker Jr. Fas (CD95) Expression is Up-Regulated on Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4246 - 4252. [Abstract] [Full Text]

				N. Mitsiades, V. Poulaki, A. Leone, and M. Tsokos Fas-Mediated Apoptosis in Ewing's Sarcoma Cell Lines by Metalloproteinase Inhibitors J Natl Cancer Inst, October 6, 1999; 91(19): 1678 - 1684. [Abstract] [Full Text] [PDF]

				F. Hensel, R. Hermann, C. Schubert, N. Abe, K. Schmidt, A. Franke, A. Shevchenko, M. Mann, H. K. Muller-Hermelink, and H. P. Vollmers Characterization of Glycosylphosphatidylinositol-linked Molecule CD55/Decay-accelerating Factor as the Receptor for Antibody SC-1-induced Apoptosis Cancer Res., October 1, 1999; 59(20): 5299 - 5306. [Abstract] [Full Text] [PDF]

				M. Shibakita, M. Tachibana, D. K. Dhar, T. Kotoh, S. Kinugasa, H. Kubota, R. Masunaga, and N. Nagasue Prognostic Significance of Fas and Fas Ligand Expressions in Human Esophageal Cancer Clin. Cancer Res., September 1, 1999; 5(9): 2464 - 2469. [Abstract] [Full Text] [PDF]

				M. Shimizu, A. Fontana, Y. Takeda, H. Yagita, T. Yoshimoto, and A. Matsuzawa Induction of Antitumor Immunity with Fas/APO-1 Ligand (CD95L)-Transfected Neuroblastoma Neuro-2a Cells J. Immunol., June 15, 1999; 162(12): 7350 - 7357. [Abstract] [Full Text] [PDF]

				R. G. Uzzo, P. Rayman, V. Kolenko, P. E. Clark, T. Bloom, A. M. Ward, L. Molto, C. Tannenbaum, L. J. Worford, R. Bukowski, et al. Mechanisms of Apoptosis in T Cells from Patients with Renal Cell Carcinoma Clin. Cancer Res., May 1, 1999; 5(5): 1219 - 1229. [Abstract] [Full Text] [PDF]

				F. Sbih-Lammali, B. Clausse, H. Ardila-Osorio, R. Guerry, M. Talbot, S. Havouis, L. Ferradini, J. Bosq, T. Tursz, and P. Busson Control of Apoptosis in Epstein Barr Virus-positive Nasopharyngeal Carcinoma Cells: Opposite Effects of CD95 and CD40 Stimulation Cancer Res., February 1, 1999; 59(4): 924 - 930. [Abstract] [Full Text] [PDF]